The oncolytic virus integrated with IL-24 and other cytokine genes was transduced into CIK cells. The genetically modified oncolytic virus would proliferate in CIK cells without destroying CIK cells. The virus harbored CIK cells were then transfused to the patient, specifically targeting the oncolytic virus to tumor cells, and ultimately destroy the tumor cells.
1. CIK cells possess non-MHC-specific and nonspecific cytotoxicity against tumor cells;
2. Oncolytic virus carried in the CIK cells would be targeted to, released into and then more
efficiently kill the tumor cells;
3. The cytokine gene integrated in the genome of the oncolytic virus is expressed in the tumor
cells along with the expansion of the virus, which directly develop the antitumor activity.
4. Using CIK cell as carrier of oncolytic virus helps to reduce the clearence of virus by receptor
immune system and otherwise some side effects caused by naked virus injection
Therefore, the combination of the oncolytic virus and CIK immune cells has a higher specificity and killing activity than CIK or oncolytic virus alone.